Objective: The Algan Hemostatic Agent (AHA) is a bioabsorbable, multi-herbal medical agent formulated to manage bleeding from surgical procedures and traumatic wounds. It is designed to be used when conventional hemostatic methods, such as compression or ligation, fail to adequately control capillary, venous, or arterial bleeding. This study aims to assess the hemostatic efficacy of AHA in two formulations—powder and liquid—using a rat tail transection model. Materials and Methods: This study included 24 Wistar Albino rats aged 10–12 weeks and weighing 250–280 g, which were randomly divided into three experimental groups (n = 8/group): 1) AHA powder, 2) AHA liquid-impregnated gauze-sponge, and 3) control (treated with a physiological saline-soaked sponge). A standardized tail transection procedure was performed on each rat to induce bleeding. Immediately following the transection, the designated treatment for each group was applied directly to the hemorrhage site. Bleeding cessation was assessed at 20-second intervals, and if bleeding persisted, the application was repeated for up to two additional attempts. Hemostasis was considered unsuccessful if bleeding continued after three consecutive applications of the assigned treatment. Results: Significantly shorter bleeding times were observed in both AHA-treated groups compared to the control group. None of the rats in the control group achieved hemostasis following three applications of the physiological saline-soaked sponge. In the AHA powder group, all 8 rats (100%) achieved hemostasis within the first 20 seconds of the initial application. In the AHA liquid-impregnated gauze-sponge group, 6 out of 8 rats (75%) achieved hemostasis after the first application, while the remaining 2 rats (25%) stopped bleeding after the second application. Statistical analysis revealed a significant difference between the control group and the two AHA-treated groups (p < 0.0001). Conclusions: These findings demonstrate the potential of AHA as a reliable hemostatic agent in both surgical settings and emergency situations where traditional methods are insufficient to control bleeding effectively. The rapid hemostasis achieved with AHA treatments suggests their utility in improving patient outcomes and minimizing blood loss in critical scenarios.
Read full abstract